Primary cutaneous B cell lymphoma during methotrexate therapy for rheumatoid arthritis.
A patient with rheumatoid arthritis developed a reversible, primary cutaneous, large B cell lymphoma during prolonged methotrexate (MTX) treatment. Regression of the skin lesions after discontinuation of the drug suggested a close relationship to MTX. Increased clinical awareness, discontinuation of MTX, and close observation are important in the initial management of this rare lymphoproliferative disorder.
Fam
A G
AG
Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada. kathy.carey@swchsc.on.ca
Perez-Ordonez
B
B
Imrie
K
K
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000139:chemically induced* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced / Q000473:pathology; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology
D018501:Antirheumatic Agents; D008727:Methotrexate